de Bruyn M - Search Results

1

Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats.

Wei Y, Chen P, de Bruyn M, Zhang W, Bremer E, Helfrich W. Wei Y, et al. Among authors: de bruyn m. BMC Gastroenterol. 2010 May 5;10:42. doi: 10.1186/1471-230X-10-42. BMC Gastroenterol. 2010. PMID: 20444253 Free PMC article.

2

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.

Bremer E, de Bruyn M, Samplonius DF, Bijma T, ten Cate B, de Leij LF, Helfrich W. Bremer E, et al. Among authors: de bruyn m, de leij lf. J Mol Med (Berl). 2008 Aug;86(8):909-24. doi: 10.1007/s00109-008-0348-9. Epub 2008 May 27. J Mol Med (Berl). 2008. PMID: 18504532 Free PMC article.

3

Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein.

Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G, Helfrich W, Haisma H. Bremer E, et al. Among authors: de bruyn m. Mol Ther. 2008 Dec;16(12):1919-26. doi: 10.1038/mt.2008.203. Epub 2008 Sep 23. Mol Ther. 2008. PMID: 18813279 Free article.

4

Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family.

Bremer E, de Bruyn M, Wajant H, Helfrich W. Bremer E, et al. Among authors: de bruyn m. Curr Drug Targets. 2009 Feb;10(2):94-103. doi: 10.2174/138945009787354593. Curr Drug Targets. 2009. PMID: 19199904 Review.

5

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W. ten Cate B, et al. Among authors: de bruyn m. Leukemia. 2009 Aug;23(8):1389-97. doi: 10.1038/leu.2009.34. Epub 2009 Mar 5. Leukemia. 2009. PMID: 19262596

6

Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology.

ten Cate B, de Bruyn M, Wei Y, Bremer E, Helfrich W. ten Cate B, et al. Among authors: de bruyn m. Curr Drug Targets. 2010 Jan;11(1):95-110. doi: 10.2174/138945010790031063. Curr Drug Targets. 2010. PMID: 20017722 Review.

7

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.

de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E. de Bruyn M, et al. Mol Cancer. 2010 Nov 23;9:301. doi: 10.1186/1476-4598-9-301. Mol Cancer. 2010. PMID: 21092273 Free PMC article.

8

Antibody-based fusion proteins to target death receptors in cancer.

de Bruyn M, Bremer E, Helfrich W. de Bruyn M, et al. Cancer Lett. 2013 May 28;332(2):175-83. doi: 10.1016/j.canlet.2010.11.006. Epub 2011 Jan 6. Cancer Lett. 2013. PMID: 21215513 Review.

9

Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling.

Bremer E, Abdulahad WH, de Bruyn M, Samplonius DF, Kallenberg CG, Armbrust W, Brouwers E, Wajant H, Helfrich W. Bremer E, et al. Among authors: de bruyn m. Immunol Lett. 2011 Aug 30;138(2):161-8. doi: 10.1016/j.imlet.2011.04.004. Epub 2011 Apr 15. Immunol Lett. 2011. PMID: 21514322

10

Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells.

de Bruyn M, Wei Y, Wiersma VR, Samplonius DF, Klip HG, van der Zee AG, Yang B, Helfrich W, Bremer E. de Bruyn M, et al. Clin Cancer Res. 2011 Sep 1;17(17):5626-37. doi: 10.1158/1078-0432.CCR-11-0303. Epub 2011 Jul 13. Clin Cancer Res. 2011. PMID: 21753155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194 results

Search Page

Filters